Navigation Links
Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
Date:2/25/2009

oval submissions targeted within the next three years. The Company's commercial strategy is to grow market share for its currently marketed products using its sales and marketing capabilities, acquire non-promoted or underperforming branded pharmaceutical products and implement life cycle management techniques to maximize the value of its currently marketed products, newly acquired products and product candidates that are in development.

Safe Harbor Statement

Statements in this press release regarding the progress and timing of our product development programs and related trials; our future opportunities; our strategy, future operations, financial position, future revenues and projected costs; our management's prospects, plans and objectives; and any other statements about management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Any statements that are not statements of historical fact (including, without limitation, statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "plans," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements.

There are a number of important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including our ability to develop and maintain the necessary sales, marketing, supply chain, distribution and manufacturing capabilities to commercialize our products, including difficulties relating to the manufacture of ZYFLO CR(R); our reliance on products marketed under Food and Drug Administration, or FDA; enforcement policies established in connection with the FDA's Drug Efficacy Study Implementation program; patient, physician and third-party
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
2. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
4. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
5. Pearl Therapeutics Secures $8 Million in Debt Financing
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
7. Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
8. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
9. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
10. Sopherion Therapeutics Secures $55 Million in Series C Funding
11. Amicus Therapeutics Announces Change to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  InterMune, Inc. (NASDAQ: ITMN ) ... 2014 financial results at the close of the U.S. ... and webcast will be hosted by InterMune at 4:30 ... investors and others may participate in the conference call ... ID#21728775. A replay of the webcast and teleconference will be ...
(Date:7/28/2014)... Research and Markets has announced the ... report to their offering. ... technique used to determine the size of a particle in ... to analyze the size of particles as it can affect ... performed to determine the behavior and nature of a material, ...
(Date:7/26/2014)... 2014 Canada Endoscopy Visualization Systems ... on the Canada Endoscopy Visualization Systems market. The ... volume (in units) and average prices (in US ... Systems, Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides company ...
(Date:7/25/2014)... 2014 Amgen (NASDAQ: AMGN ) ... $0.61 per share dividend for the third quarter of ... 2014, to all stockholders of record as of the ... About Amgen Amgen is committed to unlocking the ... by discovering, developing, manufacturing and delivering innovative human therapeutics. ...
Breaking Biology Technology:InterMune to Release Second Quarter Financial Results on August 6 2Global Particle Size Analysis Market 2014-2018 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
... causes soil to release the potent greenhouse gases methane and ... Nature reveals. "This feedback to our changing atmosphere ... warming as we previously thought," said Dr Kees Jan van ... of Natural Sciences, Trinity College Dublin, and lead author of ...
... fumes could raise the risk of heart attacks, research has ... diesel burns are harmful to blood vessels and can increase ... a heart attack or stroke. The research by the ... on healthy volunteers at levels that would be found in ...
... scale, the tiniest bridge of gold -- that made of ... new research by engineers at the University at Buffalo,s Laboratory ... experiments probing the characteristics of atomic-scale necks of gold that ... pushed into a flat, gold surface. An examination of these ...
Cached Biology Technology:New research reveals soil microbes accelerate global warming 2Diesel fumes pose risk to heart as well as lungs, study shows 2Narrowest bridges of gold are also the strongest, study finds 2
(Date:7/25/2014)... engineering at the University of Houston, has written ... organ development., "Introduction to Tissue Engineering: Applications and ... the field of artificial organ development. Metin Akay, ... UH, served as a series editor on the ... published books on the subject of growing artificial ...
(Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
(Date:7/25/2014)... puberty is influenced by ,imprinted genes,a subset of genes whose ... This is the first evidence that imprinted genes can control ... study were published today in the journal Nature . ... a marker for the timing of puberty in females. ... girls, is an inherited trait, and is linked to breast ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2Could age of first period influence development of diseases in older women? 2
... The world is composed of multiple languages, cultures, races and ... possible that the world is more united through our ears. ... at Case Western Reserve University, proposes that our musical conceptualization ... found the commonality among children of distinct ethnic backgrounds and ...
... 31 May 2011 - Parliamentarians from across the ... today for the 17th EUREKA Inter-Parliamentary Conference. They ... market-oriented R&D projects and to ,fostering a culture ... and Technology Committee head Meir Sheetrit, in the ...
... Adelaide acoustics researchers are investigating the causes of wind ... and solving ,wind turbine syndrome,. They are also ... from wind farms so they can accurately and quickly ... methods. Research leader Dr Con Doolan, of the ...
Cached Biology News:1 world, 1 sound 21 world, 1 sound 3Noise research to combat 'wind turbine syndrome' 2
... has joined forces with the Mickle Laboratory ... Tissue Chopper. This tissue sectioning system has ... for metabolic experiments and to be especially ... at biopsy or from small organs. Its ...
... The Vibratome Company has joined forces ... introduce the Vibratome 800 Tissue Chopper. This ... prepare sections of tissue for metabolic experiments ... and irregular specimens available at biopsy or ...
... Custom design, The Bioactive peptides are molecules ... a biological behaviour or activity which can ... pharmaceutical, diagnostic, chemical and agro-food applications. In ... modified peptides with superior properties for therapeutic ...
... are stored within neurons in vesicles ... in the synaptic bouton. Synaptosomes ... from other cellular debris. Abnormalites ... in many pathological condtions. Conditions ...
Biology Products: